The Administration of Tranexamic Acid For Complex Spine Surgery

Area of Science:

• Orthopedic Surgery
• Anesthesiology
• Hematology

Background:

• Instrumented spinal surgeries, numbering 1.62 million annually in the US, often involve significant blood loss due to complex procedures and the spine's vascularity.
• Excessive intraoperative blood loss predicts postoperative morbidity and necessitates transfusions.
• Antifibrinolytic medications are used to mitigate perioperative bleeding in high-risk surgeries.

Purpose of the Study:

• To evaluate the efficacy and safety of tranexamic acid (TXA) in reducing blood loss during major or complex spine surgery.
• To investigate the impact of different TXA dosing regimens on perioperative outcomes.
• To address the existing ambiguity surrounding optimal TXA dosage for multilevel spine procedures.

Main Methods:

• Review of current evidence on the use of tranexamic acid (TXA), a lysine analog that inhibits plasminogen activation.
• Analysis of studies comparing intravenous and topical TXA administration in perioperative settings.
• Examination of recent data comparing high-dose versus low-dose TXA regimens in spine surgery patients.

Main Results:

• Perioperative administration of TXA (intravenous and topical) safely and effectively reduces blood loss, transfusion needs, and hospital stay in complex spine surgery.
• Recent evidence indicates high-dose TXA significantly decreases perioperative blood loss compared to low-dose TXA.
• No increase in perioperative morbidity or mortality was observed with high-dose TXA administration.

Conclusions:

• Tranexamic acid is a valuable tool for managing blood loss in major and complex spine surgeries.
• Higher doses of TXA appear more effective in reducing blood loss without compromising patient safety.
• Implementing evidence-based high-dose TXA regimens can enhance surgical outcomes and improve blood product management.